NOD2 triggers an interleukin-32–dependent human dendritic cell program in leprosy

[1]  D. Cho,et al.  IL-32γ Induces the Maturation of Dendritic Cells with Th1- and Th17-Polarizing Ability through Enhanced IL-12 and IL-6 Production , 2011, The Journal of Immunology.

[2]  G. Kaplan,et al.  Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. , 2010, The Journal of infectious diseases.

[3]  Hua Huang,et al.  IL-32 Is a Host Protective Cytokine against Mycobacterium tuberculosis in Differentiated THP-1 Human Macrophages , 2010, The Journal of Immunology.

[4]  G. Cheng,et al.  Divergence of macrophage phagocytic and antimicrobial programs in leprosy. , 2009, Cell host & microbe.

[5]  J. Richardus,et al.  Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. , 2009, The Journal of infectious diseases.

[6]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[7]  J. Adams,et al.  IL-15 Links TLR2/1-Induced Macrophage Differentiation to the Vitamin D-Dependent Antimicrobial Pathway , 2008, The Journal of Immunology.

[8]  C. Dinarello,et al.  Endogenous IL-32 Controls Cytokine and HIV-1 Production1 , 2008, The Journal of Immunology.

[9]  Richard D. Wells,et al.  Human TLR1 Deficiency Is Associated with Impaired Mycobacterial Signaling and Protection from Leprosy Reversal Reaction , 2008, PLoS neglected tropical diseases.

[10]  Jianguo Wu,et al.  Activation of Interleukin-32 Pro-Inflammatory Pathway in Response to Influenza A Virus Infection , 2008, PloS one.

[11]  L. Joosten,et al.  Interleukin-32 induces the differentiation of monocytes into macrophage-like cells , 2008, Proceedings of the National Academy of Sciences.

[12]  H. Deeg,et al.  Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function , 2008, Proceedings of the National Academy of Sciences.

[13]  G. Cheng,et al.  LILRA2 Activation Inhibits Dendritic Cell Differentiation and Antigen Presentation to T Cells1 , 2007, The Journal of Immunology.

[14]  M. Kelliher,et al.  NOD2 Pathway Activation by MDP or Mycobacterium tuberculosis Infection Involves the Stable Polyubiquitination of Rip2* , 2007, Journal of Biological Chemistry.

[15]  S. Rabizadeh,et al.  Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences , 2007, Immunology.

[16]  A. Takayanagi,et al.  Epithelial overexpression of interleukin‐32α in inflammatory bowel disease , 2007 .

[17]  R. Tapping,et al.  Cutting Edge: A Common Polymorphism Impairs Cell Surface Trafficking and Functional Responses of TLR1 but Protects against Leprosy1 , 2007, The Journal of Immunology.

[18]  L. Joosten,et al.  Mycobacterium tuberculosis Induces Interleukin-32 Production through a Caspase- 1/IL-18/Interferon-γ-Dependent Mechanism , 2006, PLoS medicine.

[19]  J. Pieters.  Faculty Opinions recommendation of Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. , 2006 .

[20]  Do-Young Yoon,et al.  IL-32, a proinflammatory cytokine in rheumatoid arthritis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Netea,et al.  NOD2 and Toll-Like Receptors Are Nonredundant Recognition Systems of Mycobacterium tuberculosis , 2005, PLoS pathogens.

[22]  T. Graeber,et al.  TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells , 2005, Nature Medicine.

[23]  D. Malhotra,et al.  TLR2 Arg677Trp polymorphism in leprosy: revisited , 2005, Human Genetics.

[24]  T. Kang,et al.  Differential production of interleukin‐10 and interleukin‐12 in mononuclear cells from leprosy patients with a Toll‐like receptor 2 mutation , 2004, Immunology.

[25]  Masahiro Yamamura,et al.  Use of Genetic Profiling in Leprosy to Discriminate Clinical Forms of the Disease , 2003, Science.

[26]  U. Göbel,et al.  High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR , 2003, Journal of Molecular Medicine.

[27]  S. Akira,et al.  Activation and regulation of Toll-like receptors 2 and 1 in human leprosy , 2003, Nature Medicine.

[28]  A. Aderem,et al.  Cutting Edge: A Toll-Like Receptor 2 Polymorphism That Is Associated with Lepromatous Leprosy Is Unable to Mediate Mycobacterial Signaling1 , 2003, The Journal of Immunology.

[29]  R. Gazzinelli.  Faculty Opinions recommendation of Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. , 2003 .

[30]  M. Chamaillard,et al.  Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection* , 2003, The Journal of Biological Chemistry.

[31]  T. Kang,et al.  A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. , 2002, Cytokine.

[32]  S. Akira,et al.  Cutting Edge: Role of Toll-Like Receptor 1 in Mediating Immune Response to Microbial Lipoproteins1 , 2002, The Journal of Immunology.

[33]  Tatyana Chernova,et al.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.

[34]  T. Kang,et al.  Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. , 2001, FEMS immunology and medical microbiology.

[35]  B. Bloom,et al.  Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. , 1999, Science.

[36]  S. Porcelli,et al.  CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. , 1999, Journal of immunology.

[37]  C. Janeway,et al.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.

[38]  P. Brennan,et al.  CD1-restricted T cell recognition of microbial lipoglycan antigens. , 1995, Science.

[39]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[40]  J. Abrams,et al.  Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. , 1993, Journal of immunology.

[41]  C. Bucana,et al.  Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid) , 1992, Cancer Immunology, Immunotherapy.

[42]  K. Weinberg,et al.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions. , 1991, Science.

[43]  J. Convit,et al.  Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. , 1991, Science.

[44]  B. Bloom.  Learning from leprosy: a perspective on immunology and the Third World. , 1986, Journal of immunology.

[45]  C. Taylor,et al.  T lymphocyte subsets in the skin lesions of patients with leprosy. , 1983, Journal of the American Academy of Dermatology.

[46]  R. Germain,et al.  Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP). , 1978, Journal of immunology.

[47]  L. Chedid,et al.  Stimulation of an enhanced in vitro immune response by a synthetic adjuvant, muramyl dipeptide. , 1978, Journal of immunology.

[48]  E. Lederer,et al.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. , 1974, Biochemical and biophysical research communications.

[49]  E. Lederer,et al.  Adjuvant activity of monomeric bacterial cell wall peptidoglycans. , 1974, Biochemical and biophysical research communications.

[50]  D. Morton,et al.  Immunological factors which influence response to immunotherapy in malignant melanoma. , 1970, Surgery.

[51]  Ridley Ds,et al.  Classification of leprosy according to immunity. A five-group system. , 1966 .

[52]  W. Coley,et al.  THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELAS: WITH A REPORT OF TEN ORIGINAL CASES , 1893 .

[53]  D. Ridley,et al.  Classifi cation of Leprosy According to Immunity , 2012 .

[54]  M. Netea,et al.  Genomewide association study of leprosy. , 2010, The New England journal of medicine.

[55]  C. L. Silva,et al.  Mycobacterium leprae 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. , 1992, Microbial pathogenesis.

[56]  W. Coley.  The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .

[57]  D. Ridley.  Histological classification and the immunological spectrum of leprosy. , 1974, Bulletin of the World Health Organization.

[58]  R. Walker.  β ℕ Revisited , 1974 .

[59]  D. Ridley,et al.  Classification of leprosy according to immunity. A five-group system. , 1966, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.